Pharmaceutical innovation is at a turning point. For decades, chemical intermediates have been the backbone of APIs and excipients. But the next wave of progress lies in biomanufacturing, where biotechnology transforms renewable feedstocks into pharma-grade functional ingredients — in fewer steps, with reduced environmental impact, and with unprecedented control over functionality and performance.

This Keynote Session will highlight how biomanufacturing reshapes both sides of the pharma value chain:

• Excipients & Functional Ingredients: Fermentation- and bio-based polymers, polysaccharides, and stabilizers offering better solubility, bioavailability, and patient compliance, with a sustainability advantage.
• Integrated Bioprocessing: The promise of “one-step” biomanufacturing platforms where both actives and excipients can be derived from the same biological system, reducing complexity and boosting resilience.

Strategic Perspectives:

• Sustainability & ESG: Meeting pharma’s rising demand for greener supply chains and reducing the carbon footprint of formulations.
• Innovation in Functionality: Designing new excipients with novel functionalities (e.g., targeted delivery, controlled release, enhanced stability).
• Regulatory & Market Readiness: Aligning with the EU Biotech Act and regulatory frameworks to accelerate market adoption.